Cargando…

A randomized controlled trial of a new intervention in early symptomatic syndromes eliciting neurodevelopmental clinical examinations: PR-ESSENCE

The need for effective intervention programs for youth with neurodevelopmental problems (ESSENCE) and challenging behaviour is great. This study examines Problem Resolution in ESSENCE (PR-ESSENCE), a newly developed model in which children and parents develop mutual problem resolution strategies. Te...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Mats, Gillberg, Carina, Vinsa, Ingrid, Fransson, Gunnar, Samuelsson, Lena, Jakobsson, Klara, Östlund, Sven, Fernell, Elisabeth, Gillberg, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908639/
https://www.ncbi.nlm.nih.gov/pubmed/34218336
http://dx.doi.org/10.1007/s00787-021-01837-z
_version_ 1784884407521247232
author Johnson, Mats
Gillberg, Carina
Vinsa, Ingrid
Fransson, Gunnar
Samuelsson, Lena
Jakobsson, Klara
Östlund, Sven
Fernell, Elisabeth
Gillberg, Christopher
author_facet Johnson, Mats
Gillberg, Carina
Vinsa, Ingrid
Fransson, Gunnar
Samuelsson, Lena
Jakobsson, Klara
Östlund, Sven
Fernell, Elisabeth
Gillberg, Christopher
author_sort Johnson, Mats
collection PubMed
description The need for effective intervention programs for youth with neurodevelopmental problems (ESSENCE) and challenging behaviour is great. This study examines Problem Resolution in ESSENCE (PR-ESSENCE), a newly developed model in which children and parents develop mutual problem resolution strategies. Ten-week randomized controlled trial of PR-ESSENCE for children and adolescents aged 5–18 years, compared to treatment as usual. Outcomes were assessed at baseline and randomized period endpoint. Primary outcome was the Clinical Global Impression—Improvement scale (CGI-I) rated by blinded assessors. Secondary outcomes were rated by parents—SNAP-IV, Eyberg Child Behavior Inventory (ECBI), Relationship Problems Questionnaire, Family Burden of Illness Module, and children—Beck Youth Inventories (BYI). ClinicalTrials.gov identifier: NCT03780413. The study enrolled 108 participants (active n = 72; controls n = 36, randomized 2:1), of whom 95 completed the randomized period. No clinically significant group differences were found in baseline characteristics. More than half had autism and 80% had ADD or ADHD. Large treatment effects were seen on CGI-I (ITT analysis, Effect Size 1.48). Treatment responders, much/very much improved on CGI-I, were 51.4% in active group and 5.6% of controls. Effect sizes were medium to large in parent ratings on SNAP-IV (ODD and ADHD symptoms), ECBI (behaviour problems), and in BYI child self-ratings of disruptive behaviour. PR-ESSENCE treatment improved global symptoms and functioning (CGI-I), behaviour problems, ADHD and ODD symptoms, and disruptive behaviour. Treatment effects were at least equivalent to those in previous studies of well-established Parent Management Training and Collaborative Problem Solving programs.
format Online
Article
Text
id pubmed-9908639
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-99086392023-02-10 A randomized controlled trial of a new intervention in early symptomatic syndromes eliciting neurodevelopmental clinical examinations: PR-ESSENCE Johnson, Mats Gillberg, Carina Vinsa, Ingrid Fransson, Gunnar Samuelsson, Lena Jakobsson, Klara Östlund, Sven Fernell, Elisabeth Gillberg, Christopher Eur Child Adolesc Psychiatry Original Contribution The need for effective intervention programs for youth with neurodevelopmental problems (ESSENCE) and challenging behaviour is great. This study examines Problem Resolution in ESSENCE (PR-ESSENCE), a newly developed model in which children and parents develop mutual problem resolution strategies. Ten-week randomized controlled trial of PR-ESSENCE for children and adolescents aged 5–18 years, compared to treatment as usual. Outcomes were assessed at baseline and randomized period endpoint. Primary outcome was the Clinical Global Impression—Improvement scale (CGI-I) rated by blinded assessors. Secondary outcomes were rated by parents—SNAP-IV, Eyberg Child Behavior Inventory (ECBI), Relationship Problems Questionnaire, Family Burden of Illness Module, and children—Beck Youth Inventories (BYI). ClinicalTrials.gov identifier: NCT03780413. The study enrolled 108 participants (active n = 72; controls n = 36, randomized 2:1), of whom 95 completed the randomized period. No clinically significant group differences were found in baseline characteristics. More than half had autism and 80% had ADD or ADHD. Large treatment effects were seen on CGI-I (ITT analysis, Effect Size 1.48). Treatment responders, much/very much improved on CGI-I, were 51.4% in active group and 5.6% of controls. Effect sizes were medium to large in parent ratings on SNAP-IV (ODD and ADHD symptoms), ECBI (behaviour problems), and in BYI child self-ratings of disruptive behaviour. PR-ESSENCE treatment improved global symptoms and functioning (CGI-I), behaviour problems, ADHD and ODD symptoms, and disruptive behaviour. Treatment effects were at least equivalent to those in previous studies of well-established Parent Management Training and Collaborative Problem Solving programs. Springer Berlin Heidelberg 2021-07-03 2023 /pmc/articles/PMC9908639/ /pubmed/34218336 http://dx.doi.org/10.1007/s00787-021-01837-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Contribution
Johnson, Mats
Gillberg, Carina
Vinsa, Ingrid
Fransson, Gunnar
Samuelsson, Lena
Jakobsson, Klara
Östlund, Sven
Fernell, Elisabeth
Gillberg, Christopher
A randomized controlled trial of a new intervention in early symptomatic syndromes eliciting neurodevelopmental clinical examinations: PR-ESSENCE
title A randomized controlled trial of a new intervention in early symptomatic syndromes eliciting neurodevelopmental clinical examinations: PR-ESSENCE
title_full A randomized controlled trial of a new intervention in early symptomatic syndromes eliciting neurodevelopmental clinical examinations: PR-ESSENCE
title_fullStr A randomized controlled trial of a new intervention in early symptomatic syndromes eliciting neurodevelopmental clinical examinations: PR-ESSENCE
title_full_unstemmed A randomized controlled trial of a new intervention in early symptomatic syndromes eliciting neurodevelopmental clinical examinations: PR-ESSENCE
title_short A randomized controlled trial of a new intervention in early symptomatic syndromes eliciting neurodevelopmental clinical examinations: PR-ESSENCE
title_sort randomized controlled trial of a new intervention in early symptomatic syndromes eliciting neurodevelopmental clinical examinations: pr-essence
topic Original Contribution
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908639/
https://www.ncbi.nlm.nih.gov/pubmed/34218336
http://dx.doi.org/10.1007/s00787-021-01837-z
work_keys_str_mv AT johnsonmats arandomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence
AT gillbergcarina arandomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence
AT vinsaingrid arandomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence
AT franssongunnar arandomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence
AT samuelssonlena arandomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence
AT jakobssonklara arandomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence
AT ostlundsven arandomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence
AT fernellelisabeth arandomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence
AT gillbergchristopher arandomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence
AT johnsonmats randomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence
AT gillbergcarina randomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence
AT vinsaingrid randomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence
AT franssongunnar randomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence
AT samuelssonlena randomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence
AT jakobssonklara randomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence
AT ostlundsven randomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence
AT fernellelisabeth randomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence
AT gillbergchristopher randomizedcontrolledtrialofanewinterventioninearlysymptomaticsyndromeselicitingneurodevelopmentalclinicalexaminationspressence